Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease

NCT05074498 | Completed Phase 1 Results FDA Drug

• 1 other identifier: TB006AD2102
• Study Type: interventional
• Target: 154
• Locations: 1 country
• Sites: 18

Brief Summary

Part 1 of this study will be conducted to determine the safety, tolerability, and pharmacokinetic (PK) profile of multiple doses of TB006, as well as the maximum tolerated dose of TB006, and to assess the immunogenicity of TB006 (production of anti-TB006 antibody). Part 2 of this study will be conducted to determine the clinical efficacy of TB006 in participants with mild to severe Alzheimer's Disease.

Conditions

Alzheimer's Disease

Keywords

TB006; pharmacokinetics; pharmacodynamics; immunogenicity; mild to severe Alzheimer's Disease

Outcome Measures

Primary Outcomes (34)

• Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

  An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.

  Up to Day 104

• Part 1: Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatine Kinase (CK)

  Blood samples were collected for analysis of following clinical chemistry parameters including ALT, ALP, AST and CK. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

  Baseline and up to Day 104

• Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein

  Blood samples were collected for analysis of following clinical chemistry parameters including albumin and protein. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

  Baseline and up to Day 104

• Part 1: Change From Baseline in Chemistry Parameters: Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL (High Density Lipoprotein) Cholesterol, LDL (Low Density Lipoprotein) Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen

  Blood samples were collected for analysis of following clinical chemistry parameters including Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL Cholesterol, LDL Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

  Baseline and up to Day 104

• Part 1: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1C

  Blood samples were collected for analysis of following clinical chemistry parameters including Hemoglobin A1C. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

  Baseline and up to Day 104

• Part 1: Change From Baseline in Clinical Chemistry Parameters: Potassium and Sodium

  Blood samples were collected for analysis of following clinical chemistry parameters including Potassium and Sodium. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

  Baseline and up to Day 104

• Part 1: Change From Baseline in Clinical Chemistry Parameter: Thyrotropin

  Blood samples were collected for analysis of following clinical chemistry parameters including Thyrotropin. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

  Baseline and up to Day 104

• Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets

  Blood samples were collected for analysis of following hematology parameters including Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

  Baseline and up to Day 104

• Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Hemoglobin (Ery. MCH)

  Blood samples were collected for analysis of following hematology parameter: Ery. MCH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

  Baseline and up to Day 104

• Part 1: Change From Baseline in Hematology Parameter: Hematocrit

  Blood samples were collected for analysis of following hematology parameter: Hematocrit. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

  Baseline and up to Day 104

• Part 1: Change From Baseline in Hematology Parameter: Erythrocytes and Reticulocytes

  Blood samples were collected for analysis of following hematology parameter: Erythrocytes and Reticulocytes. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

  Baseline and up to Day 104

• Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Volume (Ery. MCV)

  Blood samples were collected for analysis of following hematology parameter: Ery. MCV. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

  Baseline and up to Day 104

• Part 1: Change From Baseline in Hematology Parameter: Hemoglobin

  Blood samples were collected for analysis of following hematology parameter: Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

  Baseline and up to Day 104

• Part 1: Change From Baseline in Urine Potential of Hydrogen (pH)

  Urine samples were collected for analysis of Urine pH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

  Baseline and up to Day 104

• Part 1: Change From Baseline in Urine Specific Gravity

  Urine samples were collected for analysis of Urine specific gravity. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

  Baseline and up to Day 104

• Part 1: Change From Baseline in Urobilinogen

  Urine samples were collected for analysis of Urobilinogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.

  Baseline and up to Day 104

• Part 1: Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)

  Vital signs including DBP and SBP was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

  Baseline and Up to Day 104

• Part 1: Change From Baseline in Respiratory Rate

  Vital signs including respiratory rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

  Baseline and Up to Day 104

• Part 1: Change From Baseline in Temperature

  Vital signs including temperature was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

  Baseline and Up to Day 104

• Part 1: Change From Baseline in Heart Rate

  Vital signs including heart rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

  Baseline and Up to Day 104

• Part 1: Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate

  12-lead ECG measurements was obtained using an ECG machine that automatically calculates the heart rate. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value value.

  Baseline and Up to Day 104

• Part 1: Change From Baseline in ECG Parameters

  12-lead ECG measurements was obtained using an ECG machine that automatically calculates the PR interval, QRS duration, QT interval and QT Corrected using Bazett's formula (QTcB). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.

  Baseline and Up to Day 104

• Part 1: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia Suicide Severity Rating Scale (C-SSRS)

  The C-SSRS is an interview-based instrument to systematically assess suicidal ideation and suicidal behavior. Number of participants that have an affirmative response to the 5 items for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and/or to the 5 items for suicidal behavior (1. Preparatory acts or behavior, 2. Aborted attempt, 3. Interrupted attempt, 4. Actual attempt, 5. Completed suicide) were reported. The total score ranges from 0 (no ideation present) to 5 (active suicidal ideation with specific plan and intent); higher scores indicate worse symptoms.

  Up to Day 104

• Part 1: Number of Participants With Clinically Significant Physical Examination Findings

  A complete physical examination included, at a minimum, assessment of the Cardiovascular, Respiratory, Gastrointestinal and Neurological systems. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.

  Up to Day 104

• Part 1: Number of Participants With Clinically Significant Neurological Examination Findings

  The neurological examination assessed mental status, motor and sensory skills, hearing and speech, vision, coordination, and balance. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.

  Up to Day 104

• Part 1: Dose Normalized Area Under the Concentration Time Curve Over a Dosing Interval (AUCtau) of TB006

  Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis. AUCtau normalized to the actual administered dose is presented. The AUCtau was divided by the actual dose strength to get the normalized area under the concentration-time curve.

  Day 1 and Day 29

• Part 1: Time at Which Maximum Plasma Concentration Occurs (Tmax) of TB006

  Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

  At Days 1, 8 and 29

• Part 1: Dose Normalized Maximum Observed Plasma Concentration (Cmax) of TB006

  Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis. Cmax normalized to the actual administered dose is presented. The Cmax was divided by the actual dose strength to get the normalized maximum observed plasma concentration.

  At Days 1, 8 and 29

• Part 1: Concentration at the End of a Dosing Interval (Ctrough) of TB006

  Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

  Day 8 and Day 29

• Part 1: Terminal Elimination Phase Half-life (t1/2) of TB006

  Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

  At Day 29

• Part 1: Total Clearance (CL) of TB006

  Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

  At Day 29

• Part 1: Volume of Distribution (Vd) of TB006

  Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.

  At Day 29

• Part 1: Number of Participants With Anti-TB006 Antibodies (Immunogenicity of TB006)

  Plasma samples were collected at indicated time points for the determination of anti-TB006 antibodies. Plasma samples were screened for antibodies binding to TB006 and the titer of confirmed positive samples has been reported.

  Day 1 (Predose), Day 8 (Predose), Day 36 and Day 104

• Part 2: Change From Baseline Through Day 104 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score

  The Clinical Dementia Rating was obtained through semi-structured interviews of participants and informants, and cognitive functioning was rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain was rated on a five-point scale of functioning as follows: 0: no impairment; 0.5: questionable impairment; 1: mild impairment; 2: moderate impairment; and 3: severe impairment. The Clinical Dementia Rating Scale - Sum of Boxes was based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes, and higher total scores represent worse outcomes. Baseline was defined as the last available value prior to the subject receiving the first study drug infusion on Day 1. Change from Baseline value was obtained by subtracting Baseline value from post-dose visit value.

  Baseline through Day 104

Secondary Outcomes (32)

• Part 2: Change From Baseline Through Day 36 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score

  Baseline through Day 36

• Part 2: Percentage of Responders on the Clinical Dementia Rating Scale - Sum of Boxes

  At Days 36 and 104

• Part 2: Change From Baseline on Mini-Mental State Examination (MMSE) Score

  Baseline and at Days 36 and 104

• Part 2: Change From Baseline on the Neuropsychiatric Inventory (NPI) Score

  Baseline and at Days 36 and 104

• Part 2: Number of Participants With AEs and SAEs

  Up to Day 104

Study Arms (4)

Part 1: TB006

EXPERIMENTAL

Participants will be randomized to 1 of 3 ascending dose groups to receive a total of 5 once-weekly doses of TB006, infused over 1 hour.

Drug: TB006

Part 1: Placebo

PLACEBO COMPARATOR

Participants will be randomized to receive 5 once-weekly doses of matching placebo.

Drug: Placebo

Part 2: TB006

EXPERIMENTAL

Participants will receive the highest safe and well-tolerated dose identified in Part 1, infused over 1 hour. Randomization will be stratified according to severity at Baseline (mild versus moderate Alzheimer's Disease).

Drug: TB006

Part 2: Placebo

PLACEBO COMPARATOR

Participants will be randomized to receive matching placebo. Randomization will be stratified according to severity at Baseline (mild versus moderate Alzheimer's Disease).

Drug: Placebo

Interventions

TB006 DRUG

intravenous infusion

Part 1: TB006; Part 2: TB006

Placebo DRUG

intravenous infusion

Part 1: Placebo; Part 2: Placebo

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Body weight of ≥ 50 kilograms (kg) and body mass index (BMI) between 18 and 35 kg/meters squared (m\^2), inclusive
• Mini-Mental State Examination (MMSE) score of 24 or less
• Must be ambulatory
• Clinical diagnosis of Alzheimer's Disease (AD) consistent with the following:
• Probable AD, according to National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
• Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) - Criteria for Major Neurocognitive Disorder (previously dementia)
• Participants or caregiver has the ability to understand the purpose and risks of the study and provide signed and dated informed consent which includes compliance with the requirements and restrictions listed in the inform consent form (ICF) and in this protocol. Participants whose caregiver signs the informed consent must provide their assent.

You may not qualify if:

• Any medical or neurological condition other than AD that in the opinion of the investigator could be a contributing cause of the participant's dementia (e.g., medication use, vitamin B12 deficiency, abnormal thyroid function, stroke or other cerebrovascular condition, diffuse Lewy body disease, head trauma)
• History within the past 6 months or evidence of clinically significant psychiatric illness (e.g., major depression, schizophrenia, or bipolar affective disorder)
• Diagnosis of a dementia-related central nervous system (CNS) disease other than AD (e.g., Parkinson's Disease, Huntington's Disease, frontotemporal dementia, multi-infarct dementia, dementia with Lewy bodies, normal pressure hydrocephalus)
• Identification of other known cause of dementia or any other clinically significant contributing co-morbid pathologies at screening magnetic resonance imaging (MRI), in the opinion of the investigator
• Participation in any other drug, biologic, device, or clinical study or treatment with any investigational drug or approved therapy for investigational use within 30 days (or 5 half lives, whichever is longer) prior to screening, and/or participation in any other clinical study involving experimental medications for AD within the 60 days (or 5 half lives, whichever is longer) prior to screening

Sponsors & Collaborators

• TrueBinding, Inc.: lead

Study Sites (18)

Clinical Trial Site

Garden Grove, California, 92845, United States

Location

Clinical Trial Site

San Diego, California, 92103, United States

Location

Clinical Trial Site

Delray Beach, Florida, 33445, United States

Location

Clinical Trial Site

Lady Lake, Florida, 32159, United States

Location

Clinical Trial Site #1

Maitland, Florida, 32751, United States

Location

Clinical Trial Site

Maitland, Florida, 32751, United States

Location

Clinical Trial Site

Miami, Florida, 33126, United States

Location

Clinical Trial Site

Miami, Florida, 33135, United States

Location

Clinical Trial Site

Miami, Florida, 33137, United States

Location

Clinical Trial Site

Miami, Florida, 33165, United States

Location

Clinical Trial Site

Stuart, Florida, 34997, United States

Location

Clinical Trial Site

West Palm Beach, Florida, 33407, United States

Location

Clinical Trial Site

Winter Park, Florida, 32789, United States

Location

Clinical Trial Site

Winter Park, Florida, 32792, United States

Location

Clinical Trial Site

Decatur, Georgia, 30033, United States

Location

Clinical Trial Site

Matthews, North Carolina, 28105, United States

Location

Clinical Trial Site

DeSoto, Texas, 75115, United States

Location

Clinical Trial Site

Fairfax, Virginia, 22031, United States

Location

MeSH Terms

Conditions

Alzheimer Disease

Interventions

TB006

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Results Point of Contact

• Title: Dongxu Sun
• Organization: Truebinding, Inc

info@truebinding.com

650-847-1117

Study Officials

• TrueBinding, Inc.

  TrueBinding, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 24, 2021
• First Posted: October 12, 2021
• Study Start: October 8, 2021
• Primary Completion: October 13, 2022
• Study Completion: October 13, 2022
• Last Updated: November 18, 2023
• Results First Posted: November 18, 2023

Record last verified: 2023-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (18)